Brought to you by 
Celgene gets option to acquire VentiRx through new TLR8 agonist development deal
11 Jan 2016
Executive Summary
VentiRx Pharmaceuticals Inc. (immunotherapies for cancer, respiratory, and inflammatory diseases) has granted Celgene Corp. exclusive worldwide rights its Toll-like receptor-8 agonist VTX2337, which is in Phase II trials for cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene gets option to acquire VentiRx through new TLR8 agonist development deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice